{"id":353,"date":"2019-09-09T21:05:14","date_gmt":"2019-09-10T01:05:14","guid":{"rendered":"http:\/\/labs.icahn.mssm.edu\/chehadelab\/?page_id=353"},"modified":"2022-12-28T13:19:32","modified_gmt":"2022-12-28T18:19:32","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"

Clinical Trials<\/em><\/strong><\/span><\/h1>\n

Enrolling<\/strong><\/h3>\n
    \n
  1. A Phase 3,\u00a0 Randomized,\u00a0 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis.<\/a> -Sponsor: Regeneron<\/li>\n
  2. A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), and Colitis (EC)<\/a> – Sponsor: NIH (U54- CEGIR<\/a>)<\/li>\n
  3. A Phase 3,\u00a0 Randomized,\u00a0 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis.<\/a> -Sponsor: Regeneron<\/li>\n
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and\/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) Who Have an Inadequate Response with, Lost Response to, or Were Intolerant to Standard Therapies\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 -Sponsor: Allakos<\/li>\n
  5. Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis<\/a>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -Sponsor: Adare<\/li>\n
  6. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis\u00a0\u00a0\u00a0\u00a0<\/a> – Sponsor: Regeneron<\/li>\n
  7. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA)\u00a0\u00a0 \u00a0 \u00a0 \u00a0 – Sponsor:AstraZeneca<\/li>\n
  8. Validation of The Food Frequency Questionnaire (FFQ) for EGIDs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 – Sponsor: Icahn School of Medicine<\/li>\n
  9. Prevalence of feeding dysfunction in children with eosinophilic esophagitis (EoE)\u00a0\u00a0\u00a0 \u00a0\u00a0 – Sponsor: Icahn School of Medicine<\/li>\n<\/ol>\n

     <\/p>\n

    Active but closed for enrollment<\/strong><\/h3>\n
      \n
    1. A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) with Eosinophilic Esophagitis<\/a> Sponsor: Shire<\/li>\n
    2. Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet followed by Swallowed Glucocorticoid<\/a>Sponsor: NIH (U54- CEGIR<\/a>)<\/li>\n
    3. Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) followed by Swallowed Glucocorticoid Trial (CEGIR 7802)<\/a> \u2013 Sponsor: NIH (U54- CEGIR)<\/a><\/li>\n<\/ol>\n
        \n
      1. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients with Eosinophilic Gastritis with or without Eosinophilic Gastroenteritis<\/a> Sponsor: Allakos<\/li>\n
      2. A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and\/or Eosinophilic Gastroenteritis<\/a>-Sponsor: Allakos<\/li>\n<\/ol>\n

         <\/p>\n

        Completed<\/strong><\/h3>\n
          \n
        1. A Randomized,\u00a0 Double-Blind,\u00a0 Parallel,\u00a0 Placebo-Controlled Study of the Efficacy,\u00a0 Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis<\/a> Sponsor: Regeneron<\/li>\n
        2. Development,\u00a0 validation and evaluation of an adult and pediatric eosinophilic esophagitis activity index- A prospective multicenter study.<\/a> Sponsor: University of Bern, Switzerland<\/li>\n<\/ol>\n
            \n
          1. Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years<\/a> Sponsor: Ception Therapeutics<\/li>\n
          2. A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55 mg\/kg, 2.5 mg\/kg or 10 mg\/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219).<\/a> Sponsor: GlaxoSmithKline<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

            Clinical Trials Enrolling A Phase 3,\u00a0 Randomized,\u00a0 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis. -Sponsor: Regeneron A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), and Colitis (EC) […]<\/p>\n","protected":false},"author":88,"featured_media":0,"parent":0,"menu_order":30,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-353","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/pages\/353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/users\/88"}],"replies":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/comments?post=353"}],"version-history":[{"count":18,"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/pages\/353\/revisions"}],"predecessor-version":[{"id":733,"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/pages\/353\/revisions\/733"}],"wp:attachment":[{"href":"https:\/\/labs.icahn.mssm.edu\/chehadelab\/wp-json\/wp\/v2\/media?parent=353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}